Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (631-640 of 993) with videos related to

Pageof 100
Sort By:
World Journal of Urology|July 23, 2016
Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional studyNarhari Timilshina, Veronique Ouellet, Shabbir M H Alibhai, et al.
Prostate International|March 9, 2022
Up- and downgrading in single intermediate-risk positive biopsy core prostate cancerBenedikt Hoeh, Rocco Flammia, Lukas Hohenhorst, et al.
Clinical Genitourinary Cancer|August 13, 2020
Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment ModalitiesMarina Deuker, Thomas Martin, Franziska Stolzenbach, et al.
Annals of Surgical Oncology|May 22, 2025
Perioperative Complications and In-hospital Mortality After Cystectomy for Nonbladder Cancer Conditions Versus Radical Cystectomy for Bladder CancerNatali Rodriguez Peñaranda, Mario de Angelis, Carolin Siech, et al.
Prostate Cancer and Prostatic Diseases|October 8, 2022
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideYaoYao Pollock, Matthew R Smith, Fred Saad, et al.
Journal of Clinical Medicine|March 28, 2026
Cancer-Specific Mortality in Sarcomatoid Renal Cell Carcinoma: A Histological Subtype-Controlled AnalysisMichele Nicolazzini, Calogero Catanzaro, Federico Polverino, et al.
Cancers|April 12, 2022
High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific MortalityCharles Dariane, Sylvie Clairefond, Benjamin Péant, et al.
The Lancet. Oncology|September 4, 2025
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trialTamim Niazi, Fred Saad, Steven Tisseverasinghe, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysisMike Wenzel, Marina Deuker, Luigi Nocera, et al.
International Urology and Nephrology|April 16, 2026
Racial/ethnic differences in time to nephrectomy and its association with cancer-specific mortality in localized renal cell carcinomaMaximilian Filzmayer, Federico Polverino, Michele Petix, et al.
Pageof 100

Showing results (631-640 of 993) with videos related to

Sort By:
Pageof 100
World Journal of Urology|July 23, 2016
Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional studyNarhari Timilshina, Veronique Ouellet, Shabbir M H Alibhai, et al.
Prostate International|March 9, 2022
Up- and downgrading in single intermediate-risk positive biopsy core prostate cancerBenedikt Hoeh, Rocco Flammia, Lukas Hohenhorst, et al.
Clinical Genitourinary Cancer|August 13, 2020
Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment ModalitiesMarina Deuker, Thomas Martin, Franziska Stolzenbach, et al.
Annals of Surgical Oncology|May 22, 2025
Perioperative Complications and In-hospital Mortality After Cystectomy for Nonbladder Cancer Conditions Versus Radical Cystectomy for Bladder CancerNatali Rodriguez Peñaranda, Mario de Angelis, Carolin Siech, et al.
Prostate Cancer and Prostatic Diseases|October 8, 2022
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideYaoYao Pollock, Matthew R Smith, Fred Saad, et al.
Journal of Clinical Medicine|March 28, 2026
Cancer-Specific Mortality in Sarcomatoid Renal Cell Carcinoma: A Histological Subtype-Controlled AnalysisMichele Nicolazzini, Calogero Catanzaro, Federico Polverino, et al.
Cancers|April 12, 2022
High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific MortalityCharles Dariane, Sylvie Clairefond, Benjamin Péant, et al.
The Lancet. Oncology|September 4, 2025
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trialTamim Niazi, Fred Saad, Steven Tisseverasinghe, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysisMike Wenzel, Marina Deuker, Luigi Nocera, et al.
International Urology and Nephrology|April 16, 2026
Racial/ethnic differences in time to nephrectomy and its association with cancer-specific mortality in localized renal cell carcinomaMaximilian Filzmayer, Federico Polverino, Michele Petix, et al.
Pageof 100